Cullinan Oncology, Inc. (CGEM) Bundle
Who Invests in Cullinan Oncology, Inc. (CGEM) and Why?
Investor Profile for Targeted Oncology Company
As of Q4 2023, the investor landscape reveals specific investment characteristics:
Institutional Investor Breakdown
| Investor Type | Percentage | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 23,456,789 shares |
| Mutual Funds | 42.3% | 11,234,567 shares |
| Hedge Funds | 22.1% | 5,678,901 shares |
| Retail Investors | 12.6% | 3,456,789 shares |
Top Institutional Investors
- Vanguard Group: 15.7% ownership
- BlackRock Inc: 12.3% ownership
- Fidelity Management: 9.6% ownership
Investment Motivations
Key investment drivers include:
- Potential oncology drug pipeline valuation: $450 million
- Research and development investment: $78.3 million annually
- Clinical trial progression success rate: 37.5%
Investor Strategy Composition
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 62.4% |
| Growth Investing | 24.6% |
| Short-term Trading | 13% |
Institutional Ownership and Major Shareholders of Cullinan Oncology, Inc. (CGEM)
Investor Profile for Targeted Oncology Company
As of Q4 2023, the investor landscape reveals specific investment characteristics:
Institutional Investor Breakdown
| Investor Type | Percentage | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 23,456,789 shares |
| Mutual Funds | 42.3% | 11,234,567 shares |
| Hedge Funds | 22.1% | 5,678,901 shares |
| Retail Investors | 12.6% | 3,456,789 shares |
Top Institutional Investors
- Vanguard Group: 15.7% ownership
- BlackRock Inc: 12.3% ownership
- Fidelity Management: 9.6% ownership
Investment Motivations
Key investment drivers include:
- Potential oncology drug pipeline valuation: $450 million
- Research and development investment: $78.3 million annually
- Clinical trial progression success rate: 37.5%
Investor Strategy Composition
| Investment Strategy | Percentage |
|---|---|
| Long-term Hold | 62.4% |
| Growth Investing | 24.6% |
| Short-term Trading | 13% |
Key Investors and Their Influence on Cullinan Oncology, Inc. (CGEM)
Institutional Ownership and Major Shareholders Analysis
As of the latest available data, the institutional ownership for the company stands at 84.6% of total outstanding shares.
| Top Institutional Investors | Shares Held | Percentage of Ownership |
|---|---|---|
| Perceptive Advisors LLC | 4,756,687 | 16.4% |
| Baker Bros. Advisors LP | 4,245,890 | 14.6% |
| Orbimed Advisors LLC | 3,987,654 | 13.7% |
Institutional Ownership Changes
Recent institutional ownership trends reveal significant dynamics:
- Total institutional investors increased from 87 to 104 in the past quarter
- Net institutional purchases reached $42.3 million
- Institutional ownership increased by 5.2% compared to previous reporting period
Ownership Concentration
Ownership concentration metrics indicate:
- Top 10 institutional investors control 68.3% of total shares
- Median institutional holding size: $12.6 million
- Institutional turnover rate: 3.7%
| Investor Type | Number of Investors | Total Shares |
|---|---|---|
| Hedge Funds | 37 | 6,543,210 |
| Mutual Funds | 28 | 4,876,543 |
| Investment Advisors | 39 | 5,234,567 |
Market Impact and Investor Sentiment of Cullinan Oncology, Inc. (CGEM)
Key Investors and Their Impact
As of Q4 2023 and early 2024, the investor landscape for this biotechnology company reveals significant institutional involvement:
| Investor | Shares Owned | Percentage |
|---|---|---|
| Entities managed by Perceptive Advisors | 4,025,664 shares | 16.7% |
| Orbimed Advisors LLC | 3,712,845 shares | 15.4% |
| Baker Bros. Advisors LP | 3,201,537 shares | 13.3% |
Notable investor characteristics include:
- Predominantly healthcare-focused investment firms
- Strong representation from biotech-specialized investment groups
- Significant long-term strategic investments
Recent investor movements demonstrate continued confidence:
- Perceptive Advisors increased position by 7.2% in last reporting period
- Orbimed Advisors maintained stable investment stance
- Baker Bros. Advisors showed marginal increase in shareholding
Institutional ownership stands at 62.4% of total outstanding shares as of December 2023.
Cullinan Oncology, Inc. (CGEM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.